Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their waists compared with Novo Nordisk’s rival Wegovy. Barbara ...

Shares of Septerna Inc. were soaring in Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...

Ozempic and Wegovy would no longer be covered by the state’s health insurance for low-income people under the governor’s ...

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...